Arkolith/Funds/NEA Management Company, LLC

NEA Management Company, LLC

CIK 1512848Hedge fund
Holdings as of Mar 31, 2026·disclosed May 15, 2026·~45-day 13F lag·13F-HR
Active Filer

NEA Management Company, LLC holds a concentrated book of 26 stocks worth $1.8B as of Q1 2026 (disclosed May 15, 2026, a ~45-day 13F lag). This quarter they opened Spyglass Pharma Inc and trimmed Celcuity Inc. Their largest long position is Arcellx Inc at 20% of the equity book.

Build

Build on this 13F portfolio

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.

13F holdings API

Owners, holdings, deltas, point-in-time portfolios.

stock.owners

Form 4 insider API

Open-market buys and sells, cluster scans, company flows.

insider.transactions

MCP quickstart

Connect an agent, mint a key, make the first call.

/api/mcp
Build

Ask your agent what NEA Management Company, LLC owns

This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.

Get a key Compare plans13F data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/funds/1512848/holdings"
Ask your agent
Use Arkolith to show NEA Management Company, LLC's latest
holdings, largest changes, and filing provenance.
Opened
1
new positions
Added to
2
existing
Trimmed
2
reduced
Sold out
2
exited

Concentration

Top-heavy: concentrated book

Top 5 holdings
62%
Top 10 holdings
88%
Top 20 holdings
99%

Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.

Direct sector allocation

79% mapped to company sectors

Health Care
75%
ETF / fund or unclassified
21%
Information Technology
4%

Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.

Biggest moves: latest quarter

Estimated $ traded · quarter-end prices, no cost basis

Bought
Trimmed / exited

Holdings: largest first

Bars show each stock's share of the portfolio. Click a row for its position history.

26 positions
#SecurityValueShares% PortLast moveHistory
1Arcellx, Inc.
COMMON STOCK
$349.7M3.05M
19.9%
—Held
2Celcuity Inc.
COM
$260.9M2.29M
14.8%
▼−35%
Reduced · −1.3M sh
3Spyglass Pharma, Inc.
COM SHS
$191.5M7.39M
10.9%
▲New
New position
4Trevi Therapeutics, Inc.
COM
$157.7M13.22M
9.0%
—Held
5Savara, Inc.
COM
$133.6M24.47M
7.6%
—Held
6Monte Rosa Therapeutics, Inc.
COM
$126.5M7.69M
7.2%
—Held
7MBX Biosciences, Inc.
COM
$107.9M3.61M
6.1%
—Held
8Zenas BioPharma, Inc.
COM
$78.7M4.02M
4.5%
▲+14%
Added · +500K sh
9Coursera, Inc.
COM
$74.9M12.87M
4.3%
—Held
10Aurinia Pharmaceuticals, Inc.
COM
$58.8M3.97M
3.3%
—Held
11ORIC Pharmaceuticals, Inc.
COM
$52.2M4.12M
3.0%
—Held
12CRISPR Therapeutics AG
NAMEN AKT
$50.4M1.06M
2.9%
—Held
13Phathom Pharmaceuticals, Inc.
COM
$21.8M1.96M
1.2%
—Held
14CVRx, Inc.
COM
$19.2M2.03M
1.1%
—Held
15Korro Bio, Inc.
COM
$14.7M1.30M
0.8%
▲+19%
Added · +207K sh
16X4 Pharmaceuticals, Inc.
COM
$13.4M3.23M
0.8%
—Held
17Champions Oncology, Inc.
COM NEW
$9.9M1.71M
0.6%
—Held
18Black Diamond Therapeutics, Inc.
COM
$9.5M4.45M
0.5%
—Held
19Inventiva SA
ADS
$8.0M1.46M
0.5%
—Held
20Nkarta, Inc.
COM
$7.5M3.57M
0.4%
—Held
21LeonaBio, Inc.
COM
$4.8M464.4K
0.3%
—Held
22Senti Biosciences, Inc.
COM NEW
$3.1M3.78M
0.2%
—Held
23Marker Therapeutics, Inc.
COM NEW
$2.1M1.63M
0.1%
—Held
24OnKure Therapeutics, Inc.
COM CL A
$2.0M478.5K
0.1%
—Held
25Gossamer Bio, Inc.
COM
$329K1.00M
0.0%
▼−94%
Reduced · −17.1M sh
26ImageneBio, Inc.
COM
$250K50.0K
0.0%
—Held
Showing all 26 positions

Filing history

As-of date vs the date the SEC received each filing

QuarterAs ofFiledPositionsValueForm
Q1 2026Mar 31, 2026May 15, 202626$1.8B13F-HR
Q4 2025Dec 31, 2025Feb 17, 202627$2.0B13F-HR
Q3 2025Sep 30, 2025Nov 14, 202529$1.8B13F-HR
Q2 2025Jun 30, 2025Aug 14, 202532$1.3B13F-HR
Q1 2025Mar 31, 2025May 14, 202538$1.3B13F-HR
Q4 2024Dec 31, 2024Feb 14, 202542$1.8B13F-HR
Q3 2024Sep 30, 2024Nov 14, 202442$1.8B13F-HR
Q2 2024Jun 30, 2024Aug 14, 202441$1.3B13F-HR
Q1 2024Mar 31, 2024May 15, 202444$1.6B13F-HR
Q4 2023Dec 31, 2023Feb 14, 202444$1.5B13F-HR
Q3 2023Sep 30, 2023Nov 14, 202346$1.3B13F-HR
Q2 2023Jun 30, 2023Aug 11, 202344$1.3B13F-HR
Q1 2023Mar 31, 2023May 15, 202353$1.4B13F-HR
Q4 2022Dec 31, 2022Feb 10, 202357$1.8B13F-HR
Q3 2022Sep 30, 2022Nov 14, 202257$2.0B13F-HR
Q2 2022Jun 30, 2022Aug 15, 202257$1.9B13F-HR
Q1 2022Mar 31, 2022May 16, 202257$3.5B13F-HR
Q4 2021Dec 31, 2021Feb 14, 202258$4.9B13F-HR
Q3 2021Sep 30, 2021Nov 12, 202163$8.4B13F-HR
Q2 2021Jun 30, 2021Aug 2, 202163$7.7B13F-HR
Q1 2021Mar 31, 2021May 14, 202158$4.5B13F-HR
Q4 2020Dec 31, 2020Feb 16, 202157$3.8B13F-HR
Q3 2020Sep 30, 2020Nov 6, 202054$2.4B13F-HR
Q2 2020Jun 30, 2020Aug 5, 202046$2.5B13F-HR

Data source

Holdings from SEC EDGAR 13F-HR filings, updated quarterly ~45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. Price-derived performance is withheld until the price-source policy and freshness gate are green.